In conclusion, the use of ACEI-based treatment as a firstline antihypertensive drug for those aged 65 years or older
instead of thiazide diuretic-based (mainly hydrochlorothiazide) treatment appears to be a cost-effective strategy for the prevention of adverse cardiovascular outcomes when diabetes is
present or subsequent on-treatment development of diabetes is considered.